Status:
COMPLETED
Population Pharmacokinetics of Dexmedetomidine in ICU Patients
Lead Sponsor:
University of Turku
Conditions:
Pharmacokinetics
Eligibility:
All Genders
18+ years
Phase:
PHASE2
PHASE3
Brief Summary
Dexmedetomidine is a new, highly selective and potent alpha2-adrenoreceptor agonist registered for sedation of patients in intensive care units. Although the pharmacokinetics of dexmedetomidine have b...
Eligibility Criteria
Inclusion
- Age ≥ 18 years.
- Need for dexmedetomidine sedation (determined by the responsible physician).
- Predicted length of dexmedetomidine sedation ≥ 48 hours.
- Written informed consent from the patient or the relatives of the participating patient.
Exclusion
- A previous history of intolerance to the study drug or related compounds and additives.
- Existing significant haematological, endocrine, metabolic or gastrointestinal disease
Key Trial Info
Start Date :
October 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2010
Estimated Enrollment :
21 Patients enrolled
Trial Details
Trial ID
NCT00714857
Start Date
October 1 2007
End Date
December 1 2010
Last Update
January 3 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Turku University Hospital
Turku, Finland, FIN-20521